MapLight Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	44.09	30.73	14.42	7.61	4.1
Research & Development	198.84	138.35	68.52	49.68	27.14
Operating Expenses	242.93	169.08	82.95	57.28	31.25
Operating Income	-242.93	-169.08	-82.95	-57.28	-31.25
Interest & Investment Income	8.84	5.52	4.5	1.1	0.43
Earnings From Equity Investments	-	-	-0.99	0.99	-
Currency Exchange Gain (Loss)	-	-	-	-	0
Other Non Operating Income (Expenses)	0.54	0.31	0.11	-0.51	0.8
EBT Excluding Unusual Items	-233.55	-163.25	-79.32	-55.71	-30.02
Gain (Loss) on Sale of Investments	3.72	2.1	1.74	-	-
Pretax Income	-229.83	-161.15	-77.58	-55.71	-30.02
Net Income	-229.83	-161.15	-77.58	-55.71	-30.02
Net Income to Common	-229.83	-161.15	-77.58	-55.71	-30.02
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	31	9	1	1	1
Shares Outstanding (Diluted)	31	9	1	1	1
Shares Change	3972.13%	1079.16%	11.60%	18.43%	-
EPS (Basic)	-7.42	-18.56	-105.38	-84.45	-53.89
EPS (Diluted)	-7.42	-18.56	-105.38	-84.45	-53.89
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-175.12	-138.61	-79.59	-52.47	-27.32
Free Cash Flow Per Share	-5.65	-15.97	-108.11	-79.54	-49.05
EBITDA	-242.34	-168.51	-82.25	-56.73	-30.67
D&A For EBITDA	0.59	0.58	0.7	0.56	0.57
EBIT	-242.93	-169.08	-82.95	-57.28	-31.25

SEC Filings: 10-K · 10-Q